Анти-VEGF в лечении пролиферативной диабетической ретинопатии (обзор)

Литература:
1. Lee R, Wong TY, Sabanayagam С Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond) 2015; (2): 17. DOI: 10.1186/s40662-015-0026-2.
2. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med 2012; 366 (13): 1227-39. DOI: 10.1056/NEJM-ra1005073.
3. Witmer AN, Vrensen GF, Van Noorden CJ, Schlinge-mann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003; 22 (1): 1-29. DOI: 10.1016/s1350-9462(02)00043-5.
4. Carmeliet P. Mechanisms of angiogenesis and arterio-genesis. Nat Med 2000; 6 (4): 389-95. DOI: 10.1038/74651.
5. Файзрахманов P.P., Воропаев В.Ю., Суханова А. В., Шаталова E.O. Антиангиогенная терапия неоваскулярной возрастной макулярной дегенерации. Вестник офтальмологии 2021; 137 (1): 83-93. DOI: 10.17116/oftalma202113701183.
6. Файзрахманов P.P. Анти-VEGF терапия неоваскулярной возрастной макулярной дегенерации: от рандомизированных исследований к реальной клинической практике. Российский офтальмологический журнал 2019; 12 (2): 97-105. DOI: 10.21516/2072-0076-2019-12-2-97-105.
7. Shibuya М. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Bio-chem Mol Biol 2006; 39 (5): 469-78. DOI: 10.5483/bmbrep. 2006.39.5.469.
8. Ishida S, Usui T, Yamashiro K, et al. VEGF164 is proin-flammatory in the diabetic retina. Invest Ophthalmol Vis Sci 2003; 44 (5): 2155-62. DOI: 10.1167/iovs.02-0807.
9. Lim Jl, Spee C, Hinton DR. A comparison of hypoxia-in-ducible factor-a in surgically excised neovascular membranes of patients with diabetes compared with idiopathic epiretinal membranes in nondiabetic patients. Retina 2010; 30 (9): 1472-8. DOI: 10.1097/IAE.0b013e3181d6df09.
10. Abu El-Asrar AM, Missotten L, Geboes K. Expression of hypoxia-inducible factor-1 alpha and the protein products of its target genes in diabetic fibrovascular epiretinal membranes. Br J Ophthalmol 2007; 91 (6): 822-6. DOI: 10.1136/bjo. 2006.109876.
11. Wang X, Wang G, Wang Y. Intravitreous vascular endothelial growth factor and hypoxia-inducible factor 1a in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2009; 148 (6): 883-9. DOI: 10.1016/j.ajo.2009.07.007.
12. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 113 (10): 1695. e1-15. DOI: 10.1016/j.ophtha.2006.05.064.
13. Brucker AJ, Qin H, Antoszyk AN, et al. Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings. Arch Ophthalmol 2009; 127 (2): 132-40. DOI: 10.1001/archophthal-mol. 2008.565.
14. Googe J, Brucker AJ, Bressler NM, et al. Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina 2011; 31 (6): 1009-27. DOI: 10.1097/IAE. 0b013e318217d739.
15. Gross JG, Glassman AR, Jampol LM, et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: A randomized clinical trial. JAMA 2015; 314 (20): 2137-46. DOI: 10.1001/jama.2015.15217.
16. Bressler SB, Beaulieu WT, Glassman AR, et al. Factors associated with worsening proliferative diabetic retinopathy in eyes treated with panretinal photocoagulation or ranibizumab. Ophthalmology 2017; 124 (4): 431-9. DOI: 10.1016/j.ophtha. 2016.12.005.
17. Gross JG, Glassman AR, Liu D, et al. Five-year outcomes of panretinal photocoagulation vs. intravitreous ranibizumab for proliferative diabetic retinopathy: A randomized clinical trial. JAMA Ophthalmol 2018; (136): 1138-48. DOI: 10.1001/ja-maophthalmol.2018.3255.
18. Sivaprasad S, Prevost AT, Vasconcelos JC, et al. CLARITY Study Group. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. Lancet Lond Engl 2017; 389 (10085): 2193-2203. DOI: 10.1016/S01406736(17)31193-5.
19. Arevalo JF, Lasave AF, Wu L, et al. Intravitreal beva-cizumab for proliferative diabetic retinopathy: results from the Pan-American Collaborative Retina Study group (PACORES) at 24 months of follow-up. Retina 2017; 37 (2): 334-43. DOI: 10.1097/IAE.0000000000001181.
20. Lang GE, Stahl A, Voegeler J, et al. Efficacy and safety of ranibizumab with or without panretinal laser photocoagulation versus laser photocoagulation alone in proliferative diabetic retinopathy—the PRIDE study. Acta Ophthalmol. DOI: 10.1111/aos. 14312.
21. Arevalo JF, Maia M, Flynn HW Jr, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 2008; 92 (2): 213-6. DOI: 10.1136/bjo.2007.127142.
22. Figueira J, Fletcher E, Massin P, et al. Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study). Ophthalmology 2018; 125 (5): 691-700. DOI: 10.1016/j.ophtha.2017.12.008.
23. Chatziralli I, Dimitriou E, Theodossiadis G, et al. Intravitreal ranibizumab alone or in combination with panretinal photocoagulation for the treatment of proliferative diabetic retinopathy with coexistent macular edema: long-term outcomes of a prospective study. Acta Diabetol 2020; 57 (10): 1219-25. DOI: 10.1007/S00592-020-01548-y.
24. Abdhish RB, Karisse T, Roy WB, et al. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. JAMA Ophthalmol 2013; 131 (3): 283-93. DOI: 10.1001 /jamaophthalmol. 2013.2015.
25. Smith JM, Steel DH. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy. Co-chrane Database Syst Rev 2015; 2015 (8): CD008214. DOI: 10.1002/14651858.CD008214.pub3.
26. Zhao XY, Xia S, Chen YX. Antivascular endothelial growth factor agents pretreatment before vitrectomy for complicated proliferative diabetic retinopathy: A meta-analysis of randomised controlled trials. Br J Ophthalmol 2018; 102 (8): 1077-85. DOI: 10.1136/bjophthalmol-2017-311344.
27. Wang DY, Zhao XY, Zhang WF, et al. Perioperative anti-vascular endothelial growth factor agents treatment in patients undergoing vitrectomy for complicated proliferative diabetic retinopathy: A network meta-analysis. Sci Rep 2020; 10 (1): 18880. DOI: 10.1038/S41598-020-75896-8.
28. Бикбов M.M., Файзрахманов P.P., Каланов M.P Комбинированный подход к оперативному лечению пациентов с пролиферативной стадией диабетической ретинопатии. Саратовский научно-медицинский журнал 2017; 13 (2): 338-45.
29. Vidinova CN, Gouguchkova РТ, Dimitrov Т, et al. [Comparative clinical and ultrastructural analysis of the results from ranibizumab and aflibercept in patients with PDR]. Klin Monbl Augenheilkd 2020; 237 (1): 79-84. [in German]. DOI: 10.1055/a-0767-6951.
30. Коновалова К. И., Шишкин М.М., Файзрахманов P.P. Эффективность многоэтапного хирургического лечения пролиферативной диабетической ретинопатии, осложненной начальной катарактой. Вестник офтальмологии 2020; 136 (6): 171-6. DOI: 10.17116/oftalma2020136062171.